Dalian BIO-CHEM Company Limited (SHA:603360)
China · Delayed Price · Currency is CNY 22.66
+2.06 (10.00%)
Apr 30, 2026, 3:00 PM CST
Dalian BIO-CHEM Company Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,498 | 1,724 | 1,305 | 1,054 | 1,253 | 995.18 |
Other Revenue | - | - | 6.83 | 11.3 | 3.32 | 11.08 |
| 1,498 | 1,724 | 1,312 | 1,066 | 1,257 | 1,006 | |
Revenue Growth (YoY) | 5.38% | 31.43% | 23.09% | -15.20% | 24.88% | 34.25% |
Cost of Revenue | 946.63 | 1,100 | 737.81 | 520.77 | 616.03 | 556.52 |
Gross Profit | 551.68 | 624.21 | 573.89 | 544.89 | 640.63 | 449.74 |
Selling, General & Admin | 165.6 | 174.62 | 111.16 | 120.52 | 132.2 | 91.52 |
Research & Development | 84.28 | 84.2 | 49.65 | 38.98 | 47.09 | 40.02 |
Other Operating Expenses | -6.08 | -3.69 | 10.92 | 10.37 | 14.93 | 9.17 |
Operating Expenses | 243.8 | 255.12 | 178.98 | 168.44 | 195.05 | 144.8 |
Operating Income | 307.88 | 369.09 | 394.91 | 376.44 | 445.58 | 304.93 |
Interest Expense | - | - | -6.7 | -3.92 | -3.72 | -11.77 |
Interest & Investment Income | - | - | 32.26 | 19.12 | 3.55 | 3.75 |
Currency Exchange Gain (Loss) | - | - | 8.4 | 6.42 | 17.15 | -0.47 |
Other Non Operating Income (Expenses) | -26.02 | -15.04 | -17.88 | -13.69 | -0.63 | -0.89 |
EBT Excluding Unusual Items | 281.85 | 354.06 | 410.98 | 384.37 | 461.93 | 295.55 |
Gain (Loss) on Sale of Investments | 1.18 | 0.4 | - | 0.01 | -7.57 | 0.59 |
Gain (Loss) on Sale of Assets | -0.43 | 0.17 | - | - | 0.07 | - |
Asset Writedown | -1.13 | -1.05 | -0.26 | -0.11 | -0.26 | -0.97 |
Legal Settlements | - | - | - | - | -0.12 | -10 |
Other Unusual Items | - | - | 3.55 | 1.5 | 7.38 | 6.87 |
Pretax Income | 281.47 | 353.57 | 414.27 | 385.78 | 461.43 | 292.04 |
Income Tax Expense | 36.64 | 46.48 | 55.45 | 57.4 | 58.87 | 41.55 |
Earnings From Continuing Operations | 244.83 | 307.09 | 358.82 | 328.38 | 402.57 | 250.49 |
Minority Interest in Earnings | -72.34 | -97.32 | -13.57 | - | - | - |
Net Income | 172.49 | 209.77 | 345.26 | 328.38 | 402.57 | 250.49 |
Net Income to Common | 172.49 | 209.77 | 345.26 | 328.38 | 402.57 | 250.49 |
Net Income Growth | -50.80% | -39.24% | 5.14% | -18.43% | 60.71% | 12.96% |
Shares Outstanding (Basic) | 686 | 699 | 711 | 697 | 692 | 687 |
Shares Outstanding (Diluted) | 686 | 699 | 711 | 697 | 692 | 694 |
Shares Change (YoY) | -1.57% | -1.63% | 2.04% | 0.64% | -0.30% | -3.01% |
EPS (Basic) | 0.25 | 0.30 | 0.49 | 0.47 | 0.58 | 0.36 |
EPS (Diluted) | 0.25 | 0.30 | 0.49 | 0.47 | 0.58 | 0.36 |
EPS Growth | -50.01% | -38.23% | 3.03% | -18.95% | 61.20% | 16.46% |
Free Cash Flow | 538.7 | 510.03 | 88.07 | 322.33 | 345.62 | -49.58 |
Free Cash Flow Per Share | 0.79 | 0.73 | 0.12 | 0.46 | 0.50 | -0.07 |
Dividend Per Share | - | - | 0.429 | 0.306 | 0.292 | - |
Dividend Growth | - | - | 40.02% | 4.97% | - | - |
Gross Margin | 36.82% | 36.21% | 43.75% | 51.13% | 50.98% | 44.69% |
Operating Margin | 20.55% | 21.41% | 30.11% | 35.33% | 35.46% | 30.30% |
Profit Margin | 11.51% | 12.17% | 26.32% | 30.81% | 32.04% | 24.89% |
Free Cash Flow Margin | 35.95% | 29.59% | 6.71% | 30.25% | 27.50% | -4.93% |
EBITDA | 407.4 | 462.45 | 463.65 | 440.08 | 516.59 | 353.15 |
EBITDA Margin | 27.19% | 26.82% | 35.35% | 41.30% | 41.11% | 35.10% |
D&A For EBITDA | 99.52 | 93.36 | 68.73 | 63.64 | 71.01 | 48.22 |
EBIT | 307.88 | 369.09 | 394.91 | 376.44 | 445.58 | 304.93 |
EBIT Margin | 20.55% | 21.41% | 30.11% | 35.33% | 35.46% | 30.30% |
Effective Tax Rate | 13.02% | 13.15% | 13.38% | 14.88% | 12.76% | 14.23% |
Revenue as Reported | - | - | 1,312 | 1,066 | 1,257 | 1,006 |
Advertising Expenses | - | - | 0.22 | 0.65 | 0.14 | 0.03 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.